STAT1 and neoplasm: We found that the administration of Compound 182 to AT3-OVA tumor-bearing Lck-Cre;Ptpn2fl/fl mice did not further increase p-STAT-1 signaling (Fig. 7e, f) or T cell infiltrates (as assessed by immunohistochemistry or flow cytometry) (Fig. 7c, e), indicating that any direct effects on tumor cells and/or stromal cells are unlikely to significantly affect STAT-1 inflammatory responses and T cell recruitment.